The company said the high-dose group showed a statistically significant improvement in 90-day functional outcomes, but detailed efficacy data have not yet been disclosed.
Shaanxi Micot Pharmaceutical Technology has reported positive topline findings from a Phase II trial of MT200605, an investigational small-molecule therapy being developed for acute ischaemic stroke.
The multicentre, randomised, double-blind and placebo-controlled study enrolled 360 participants and evaluated the efficacy, safety and pharmacokinetics of MT200605, according to a voluntary announcement filed by the company with the Hong Kong Stock Exchange on 3 August 2026.
The trial’s primary efficacy endpoint was the proportion of participants achieving a modified Rankin Scale score of 0 or 1 at 90 days. A score within this range generally indicates no symptoms or no significant disability following stroke.
Micot said the proportions of participants achieving this outcome were higher in the medium- and high-dose groups than in the placebo group. The company reported that the high-dose group showed a relative increase of more than 100% over placebo and that the difference was statistically significant in a logistic regression analysis.
The company did not disclose the absolute response rates, participant numbers in each treatment arm, confidence intervals or p-values in its exchange announcement. It also did not provide sufficient statistical information to independently assess the magnitude or robustness of the reported treatment effect.
Micot said the trial’s secondary efficacy endpoints showed trends consistent with the primary finding. However, individual secondary-endpoint results were not included in the announcement.
On safety, the company reported that no serious adverse events were considered related to MT200605. Grade 3 or higher treatment-emergent adverse events were described as comparable across the treatment groups, with no new significant safety concerns identified.
The ClinicalTrials.gov record for NCT07205328 describes the study as a Phase II exploratory trial involving people diagnosed with acute ischaemic stroke within 24 hours of onset. Participants received one of three MT200605 dose levels or placebo alongside standard medical care.
MT200605 is designed to activate the brain-derived neurotrophic factor receptor TrkB and provide antioxidant activity. Micot is investigating whether these mechanisms can limit neurological injury and support functional recovery following ischaemic stroke. These proposed effects remain under clinical evaluation.
The company has not announced the next regulatory or clinical-development step for the acute ischaemic stroke programme. Full study findings have also not yet been reported in a peer-reviewed publication or a public trial-results record.
